Safety and efficacy of ponatinib in subject with chronic myeloid leukaemia who are resistant to two or more prior tyrosine kinase inhibitors.

Trial Profile

Safety and efficacy of ponatinib in subject with chronic myeloid leukaemia who are resistant to two or more prior tyrosine kinase inhibitors.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jun 2016

At a glance

  • Drugs Ponatinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Pearl
  • Most Recent Events

    • 21 Jan 2016 New trial record
    • 08 Dec 2015 Results (n=35) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top